NCT05078385View on ClinicalTrials.gov

Safety of Extracellular Vesicles for Burn Wounds

PHASE1CompletedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

September 5, 2024

Study Completion Date

November 19, 2024

Conditions

Burns

Interventions

DRUG

AGLE-102

AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)

Trial Locations (2)

27599

North Carolina Jaycee Burn Center, Chapel Hill

33136

Ryder Trauma Center, Miami

Sponsors

Lead Sponsor

Aegle Therapeutics

All Listed Sponsors

collaborator

Congressionally Directed Medical Research Programs

FED

lead

Aegle Therapeutics

INDUSTRY

NCT05078385 - Safety of Extracellular Vesicles for Burn Wounds | Biotech Hunter | Biotech Hunter